Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

0.2405
-0.0213-8.14%
Post-market: 0.2388-0.0017-0.71%19:58 EST
Volume:519.73K
Turnover:131.70K
Market Cap:6.41M
PE:-0.34
High:0.2664
Open:0.2600
Low:0.2405
Close:0.2618
52wk High:1.30
52wk Low:0.2200
Shares:26.65M
Float Shares:26.54M
Volume Ratio:1.43
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7013
EPS(LYR):-2.7203
ROE:-155.01%
ROA:-79.36%
PB:1.42
PE(LYR):-0.09

Loading ...

Company Profile

Company Name:
Adial Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
5
Office Location:
4870 Sadler Road,Suite 300,Glen Allen,Virginia,United States
Zip Code:
23060
Fax:
- -
Introduction:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Directors

Name
Position
Cary J. Claiborne
Chief Executive Officer and Director
Kevin Schuyler
Chairman of the Board
J. Kermit Anderson
Director
James W. Newman, Jr.
Director
Robertson H. Gilliland
Director
Tony Goodman
Director

Shareholders

Name
Position
Cary J. Claiborne
Chief Executive Officer and Director
Joseph Truluck
Chief Financial Officer
Bankole A. Johnson
Chief Medical Officer